Source comparison
TB-500 Research Fertility Considerations: Practical Comparison
Dosing Frequency Daily or 2–3×/week for 4–8 weeks Coordinate with estrous/menstrual cycle phase Timing matters more than total dose Baseline Markers Inflammatory cytokines, tissue histology Add estradiol, progesterone, testosterone, LH, FSH Reproductive hormon
This comparison does not assign a generated winner or score.
- Dosing Frequency
- Daily or 2–3×/week for 4–8 weeks
- Coordinate with estrous/menstrual cycle phase
- Timing matters more than total dose
- Baseline Markers
- Inflammatory cytokines, tissue histology
- Add estradiol, progesterone, testosterone, LH, FSH
- Reproductive hormones provide critical context
- VEGF Monitoring
- Optional unless angiogenesis is primary endpoint
- Recommended—track serum VEGF and tissue-level receptor expression
- VEGF is the mechanistic link between TB-500 and fertility effects
- Washout Period
- 7–14 days before tissue harvest
- Extend to 21–28 days to cover full reproductive cycle
- Tissue-level actin remodeling persists beyond serum clearance
- Subject Selection
- Exclude pregnant subjects as standard precaution
- Exclude or isolate subjects in active reproductive cycling
- Overlap with ovulation or implantation windows introduces confounds